Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ASE Technology Holding Co., Ltd. American Depositary Shares (each representing (NY:ASX)

9.545 -0.285 (-2.90%)
Streaming Delayed Price Updated: 11:07 AM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ASE Technology Holding Co., Ltd. American Depositary Shares (each representing

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Life360 Launches No Show Alerts to Ease Parents’ Back-To-School Scheduling Stress
New Feature Alerts if a Loved One Doesn’t Make It Somewhere They’re Supposed to Be, Supporting Families During the Most Chaotic Time of the Year 
From Life360, Inc.
Via GlobeNewswire
Life360 Reports Record Q2 2025 Results
From Life360, Inc.
Via GlobeNewswire
Life360 Names COO Lauren Antonoff as Chief Executive Officer
From Life360, Inc.
Via GlobeNewswire
Earnings Scheduled For July 31, 2025
 
Via Benzinga
A Peek at ASE Tech Holding Co's Future Earnings
 
Via Benzinga
Gabelli Funds to Host 31st Annual Aerospace & Defense Symposium at The Harvard Club, New York City Thursday, September 4, 2025
From Gabelli Funds
Via GlobeNewswire
OTC Markets Group Welcomes Alkane Resources Limited to OTCQX
From OTC Markets
Via GlobeNewswire
Earnings Scheduled For April 30, 2025
 
Via Benzinga
P/E Ratio Insights for ASE Technology Holding Co
 
Via Benzinga
OTC Markets Group Welcomes Talga Group Ltd. to OTCQX
From OTC Markets
Via GlobeNewswire
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
OTC Markets Group Welcomes Andean Silver Ltd to OTCQX
From OTC Markets
Via GlobeNewswire
AI & Technology Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Life360 Enhances Ad Platform With Launch of Place Ads and Uplift, Redefining Real-World Targeting and Measurement
Company introduces breakthrough ad tools that deliver brand messages based on real-world behavior and prove in-store impact with deterministic measurement 
From Life360, Inc.
Via GlobeNewswire
Life360 Announces Closing of Upsized $320 Million Offering of 0.00% Convertible Senior Notes
From Life360, Inc.
Via GlobeNewswire
Life360 Announces Pricing of Upsized Convertible Senior Notes Offering
From Life360, Inc.
Via GlobeNewswire
Life360 Proposes Convertible Senior Notes Offering
From Life360, Inc.
Via GlobeNewswire
ASE Announces FOCoS-Bridge With TSV; Latest Package Technology Reduces Power Loss by 3x for Next-Generation AI and HPC Applications
From Advanced Semiconductor Engineering, Inc.
Via Business Wire
5 Undervalued Stocks To Buy On China Tariff Cuts
 
Via Benzinga
Life360 Reports Record Q1 2025 Results
From Life360, Inc.
Via GlobeNewswire
Alterity Therapeutics Prominently Featured at the International MSA Congress
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
ATH434 Phase 2 Data to be Presented at Opening Plenary Session 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
ASE Technology Holding Co Honors Outstanding Suppliers of 2024
From ASE Technology Holding Co., Ltd.
Via Business Wire
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.